- In children with de novo acute myeloid leukemia (AML), odds of harboring t(8;21) or inv(16) cytogenetic abnormalities increased with BMI.
Why this matters
- This may be the first reported study linking BMI standard deviation score and incidence of cytogenetic abnormalities in children with AML.
- Study to investigate associations between BMI prior to therapy and outcomes in a cohort from 10 different countries of 867 children with de novo AML.
- 10 (range, 2-17) years median age at diagnosis.
- Funding: Danish Childhood Cancer Foundation, Danish Cancer Society, Novo Nordisk Foundation, Canadian Institutes of Health Research, Canadian Cancer Society Research Institute.
- No significant difference in incidence of relapse, treatment-related mortality, or overall mortality by BMI.
- Cytogenetic abnormalities among patients with available genetic data:
- 19% had t(8;21).
- 10% had inv(16).
- 12% had KMT2A rearrangement.
- Odds of harboring t(8;21) or inv(16) increased with increasing BMI vs patients with healthy weight:
- t(8;21) in overweight and obese patients: aOR=1.2 (95% CI, 0.7‐1.9) and 1.9 (95% CI, 1.1-3.4).
- inv(16) in overweight and obese patients: aOR=1.6 (95% CI, 0.8‐3.0) and 2.8 (95% CI, 1.3-5.8).
- BMI groups were assessed at diagnosis; weight change during treatment was not taken into account.